

# Evaluation of the clinical efficacy and safety of Perindopril / Indapamide / Amlodipine fixed-dose combination in single-pill versus free dual therapy at the same dose as the single-pill combination in patients with uncontrolled essential hypertension

<b>Submission date</b> 14/09/2012	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 19/10/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 18/04/2018	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

## Contact information

### Type(s)

Scientific

### Contact name

Mrs Valérie Fautrier

### Contact details

Institut de Recherche Internationales Servier  
50, rue Carnot  
Suresnes  
France  
92284

## Additional identifiers

### Protocol serial number

CL3-06593-005

# Study information

## Scientific Title

Evaluation of the clinical efficacy and safety of Perindopril / Indapamide / Amlodipine fixed-dose combination in single-pill versus free dual therapy at the same dose as the single-pill combination in patients with uncontrolled essential hypertension

## Study objectives

To evaluate the clinical efficacy and safety of fixed-dose combination Perindopril / Indapamide / Amlodipine in single-pill versus free dual therapy in patients having an uncontrolled hypertension under ongoing treatment.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

## Study design

International multicentre randomised open-label 12-week study

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Essential hypertension

## Interventions

One treatment period: Single-pill combination of Perindopril / Indapamide / Amlodipine versus free dual therapy by fixed dose combination of Perindopril / Indapamide and by Amlodipine

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Perindopril, Indapamide, Amlodipine

## Primary outcome(s)

1. Supine systolic blood pressure (SBP) and diastolic blood pressure (DBP): Change from baseline to last post-baseline assessment
2. Supine blood pressure normalisation

## Key secondary outcome(s))

1. Supine and standing SBP and DBP: Change from baseline to last post-baseline assessment
2. Supine and standing blood pressure normalisation at the last post-baseline assessment for each visit measurement
3. Adverse events
4. Blood and urine biochemistry
5. Haematology
6. Vital signs and physical examination
7. 12-lead electrocardiogram

**Completion date**

01/09/2014

## Eligibility

**Key inclusion criteria**

1. Men or women of any ethnic origin > or = 18 years old
2. Uncontrolled hypertension

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Pregnancy, breastfeeding or possibility of becoming pregnant during the study
2. Hypertension known to be resistant to diuretics or ACE inhibitors
3. Secondary hypertension
4. Complicated hypertension
5. Obesity
6. History of renal disease, ventricular rhythm disorders, atrial fibrillation, atrial flutter
7. Diabetes
8. Grapefruit juice is forbidden during the study

**Date of first enrolment**

01/01/2014

**Date of final enrolment**

01/09/2014

# Locations

## Countries of recruitment

France

Russian Federation

Serbia

## Study participating centre

Institut de Recherche Internationales Servier

Suresnes

France

92284

# Sponsor information

## Organisation

Institut de Recherches Internationales Servier (France)

## ROR

<https://ror.org/034e7c066>

# Funder(s)

## Funder type

Industry

## Funder Name

Institut de Recherches Internationales Servier (France)

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from <https://clinicaltrials.servier.com/> if a Marketing Authorisation has been granted after 2014.

## IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2017		Yes	No
<a href="#">Basic results</a>				No	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes